Foundation Medicine has received FDA clearance for its FoundationOneLiquid CDx, which will be used as a companion diagnostic for Janssen Biotech's AKEEGA in treating BRCA-mutated metastatic castration-resistant prostate cancer.
FoundationOneLiquid is a liquid biopsy test that analyzes cancer-related genes to provide genomic insights, including mutations in BRCA1 or BRCA2, useful for treating metastatic castration-resistant prostate cancer. It allows doctors to leverage a minimally invasive liquid biopsy to identify patients with BRCA mutations who may benefit from specific treatments such as AKEEGA and can help make personalized treatments more feasible.
Analyst QuickTake: In November 2023 , Foundation Medicine’s FoundationOne CDx tissue-based comprehensive genomic profiling test received FDA approval for use with AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) to treat advanced breast cancer in adults. The test uses a tissue sample to analyze cancer-related genes for genomic alterations in a patient’s tumor.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.